AP -- NEW YORK — Drugmaker Bristol-Myers Squibb Co. said Tuesday its board authorized the repurchase of up to $3 billion of its common stock. The New York company said the buyback program has no expiration date and will take place over the next few years. It said the decision reflects Bristol-Myers’ strong financial position, which included $9.8 billion in cash and marketable securities at the end of the first quarter.
